TRCT
GRCL

Tower Research Capital (TRC)’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Tower Research Capital (TRC)’s Portfolio GRCL Stock Details GRCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,465
Closed -$54.9K – 6299
2023
Q4 		$54.9K Sell
5,465
-28,969
-84% -$131K ﹤0.01% 3067
2023
Q3 		$99.2K Buy
34,434
+23,417
+213% +$85.6K ﹤0.01% 1985
2023
Q2 		$42K Buy
11,017
+3,352
+44% +$9.39K ﹤0.01% 2727
2023
Q1 		$14K Sell
7,665
-5,860
-43% -$12.3K ﹤0.01% 3934
2022
Q4 		$31K Buy
13,525
+5,168
+62% +$15.8K ﹤0.01% 2732
2022
Q3 		$27K Buy
8,357
+7,751
+1,279% +$25.2K ﹤0.01% 3705
2022
Q2 		$3K Sell
606
-1,548
-72% -$4.81K ﹤0.01% 5443
2022
Q1 		$5K Sell
2,154
-199
-8% -$678 ﹤0.01% 5137
2021
Q4 		$14K Buy
+2,353
New +$22.6K ﹤0.01% 4128

Tower Research Capital (TRC)'s GRCL Position: Q1 2024 in Review

Tower Research Capital (TRC) sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 5,465 shares — an estimated $54.9K sold.

Tower Research Capital (TRC) first reported a position in GRCL in Q4 2021 and held it in 9 quarters. The position peaked at $99.2K in Q3 2023. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

  • Tower Research Capital (TRC) reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 5,465 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $54.9K.
  • Tower Research Capital (TRC) first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q4 2021 and held it in 9 quarters.
  • Tower Research Capital (TRC)'s Gracell Biotechnologies Inc. American Depositary Shares position peaked at $99.2K in Q3 2023.
  • 0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2024, filed 15 May 2024.